Otsuka Holdings

What Otsuka Holdings does

Otsuka Holdings Co., Ltd. (大塚ホールディングス株式会社) is a Tokyo-listed (TYO:4578) Japanese healthcare conglomerate operating through four core segments: pharmaceuticals (the largest), nutraceutical and consumer products, medical devices, and IV solutions. Its pharmaceutical business — anchored by Otsuka Pharmaceutical Co., Ltd. — focuses on psychiatric and neurological disorders (ABILIFY/REXULTI franchise, centanafadine XR for ADHD, TSND-201 for PTSD following the Transcend Therapeutics acquisition) and has expanded into nephrology with the FDA-approved Voyxact (sibeprenlimab) for IgA nephropathy and the Phase-3 JNT-517 candidate for phenylketonuria. The company also markets the Paradise ultrasound renal denervation system via Recor Medical (Otsuka Medical Devices), runs a global IV-solutions JV with ICU Medical, and supplies consumer nutraceutical brands (POCARI SWEAT, Nature Made, SOYJOY, Bonafia, Calorie Mate, Oronamin C).

The business model is diversified across reimbursement-driven prescription pharmaceuticals, hospital-procured medical devices and IV solutions, and retail/e-commerce nutraceuticals. The firm deploys an enterprise field-sales GTM built on direct medical-representative (MR) forces in Japan, the US, Europe, and Asia, supplemented by event-driven engagement at major medical congresses (APSARD, ACMG, AAIC), unbranded awareness campaigns, and the FDA-cleared Rejoyn digital therapeutic that integrates software into the pharmaceutical treatment pathway. FY2025 revenue reached JPY 2,468.9 billion (approximately USD 16.51 billion), up 6.0% YoY on a business profit of JPY 446.1 billion (+3.6%), with FY2026 revenue guided to JPY 2,520 billion but business profit expected to decline 20.4% on generic competition.

Otsuka has pursued an aggressive M&A-led pipeline replenishment strategy, deploying up to USD 3.46 billion since October 2024 across Jnana Therapeutics (USD 1.1B, PKU/RAPID platform), Araris Biotech (USD 1.14B, ADC technology), and Transcend Therapeutics (USD 1.225B, PTSD neuroplastogen), while also licencing in ulefnersen from Ionis and partnering with Harbour BioMed on BCMAxCD3 bispecifics and Lundbeck on REXULTI global co-development. The portfolio carries 37,758 employees globally and trades at approximately USD 36.25 billion market capitalization with a P/E ratio near 14.7.

Name

Otsuka Holdings

Legal name

Otsuka Holdings Co., Ltd. (大塚ホールディングス株式会社)

Website

https://otsuka.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Otsuka Holdings is a Tokyo-listed Japanese healthcare conglomerate operating globally across four segments — pharmaceuticals (psychiatry, neurology, nephrology), medical devices, IV solutions, and consumer nutraceuticals (POCARI SWEAT, Nature Made, SOYJOY) — generating approximately USD 16.5 billion in FY2025 revenue from prescription drugs, hospital devices, retail consumer health products, and digital therapeutics.

Ownership category

akta.pro rank

Product category

Diversified Healthcare Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Prescription pharmaceuticals
• Psychiatric medicines
• Nutraceutical beverages
• Renal denervation devices
• Digital therapeutics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Revenue from prescription pharmaceutical products including psychiatric/neurological drugs (ABILIFY/REXULTI, ABILIFY ASIMTUFII, brexpiprazole), kidney disease treatments (Voyxact/sibeprenlimab), oncology (TS-1, TAS-102), and other therapeutic areas. Sold through direct sales teams and hospital channels globally. This is the largest revenue stream.
2. Nutraceutical and Consumer Products: Revenue from functional beverages (POCARI SWEAT), nutritional supplements (Nature Made, SOYJOY), and consumer packaged goods. Sold through retail, convenience stores, and e-commerce channels globally.
3. Medical Devices: Revenue from Otsuka Medical Devices segment including the Paradise ultrasound renal denervation system, BioMimics 3D stent system, and Tron FX thrombus removal device, sold through direct hospital sales channels.
4. IV Solutions and Hospital Products: Revenue from IV solutions manufactured by Otsuka Pharmaceutical Factory, supported by the ICU Medical joint venture for North American manufacturing and innovation.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Otsuka Holdings is a Japanese healthcare conglomerate that develops, manufactures, and sells prescription pharmaceuticals in psychiatry, neurology, nephrology, and oncology (e.g., ABILIFY, REXULTI/brexpiprazole, Voyxact/sibeprenlimab), alongside nutraceutical/functional food and beverage products (POCARI SWEAT, Nature Made, SOYJOY, Calorie Mate), medical devices including the Paradise ultrasound renal denervation system, and IV solutions. It generates the bulk of revenue from pharmaceutical product sales (JPY 2,468.9 billion in FY2025) plus consumer product sales distributed through retail, e-commerce, vending, and hospital channels.

Differentiator

Problem solved

Functional benefit

Brands

• POCARI SWEAT: Electrolyte beverage brand for hydration and health maintenance
• Nature Made
• SOYJOY
• Bonafia
• Calorie Mate
• Oronamin C
• Mariaris

Products and services

• ABILIFY / ABILIFY ASIMTUFII (aripiprazole) Branded antipsychotic / long-acting injectable aripiprazole for schizophrenia, bipolar I disorder, and other psychiatric indications, prescribed by psychiatrists and dispensed through hospital/retail pharmacy channels globally.
• REXULTI (brexpiprazole) Prescription atypical antipsychotic for schizophrenia, MDD adjunct, and Alzheimer's agitation, sold through the Otsuka-Lundbeck global collaboration.
• Voyxact (sibeprenlimab) Anti-APRIL monoclonal antibody therapy for primary IgA nephropathy, sold via nephrology specialty channels with monthly prescription billing cadence.
• TSND-201 (methylone) - rapid-acting neuroplastogen for PTSD Late-stage PTSD therapeutic candidate targeting rapid-onset neuroplasticity; positioned as the first new PTSD mechanism in approximately 25 years.
• JNT-517 (repinautrabit) for Phenylketonuria (PKU) Small molecule oral therapy in Phase 3 development aimed at lowering blood phenylalanine in patients with PKU, a rare metabolic disease.
• Centanafadine XR (for ADHD) First-in-class norepinephrine, dopamine, and serotonin triple reuptake inhibitor in late-stage development for adult ADHD, potentially with comorbid anxiety benefit.
• Paradise Ultrasound Renal Denervation System Ultrasound-based endovascular catheter system for renal denervation in patients with resistant hypertension, deployed by interventional cardiologists and nephrologists.
• BioMimics 3D Stent System Three-dimensional nitinol vascular stent for treatment of peripheral vascular disease, sold through hospital specialty channels.
• Tron FX Thrombus Removal Device Mechanical thrombectomy device for the removal of thrombus in peripheral and coronary vasculature, sold via Otsuka Medical Devices' hospital specialty channels.
• Rejoyn (Digital Therapeutic for Major Depressive Disorder) FDA-cleared prescription digital therapeutic app that delivers cognitive-emotional training as an adjunctive treatment for adults with major depressive disorder.
• POCARI SWEAT Iconic electrolyte functional beverage brand for hydration and health maintenance, sold across 17+ countries through retail, convenience stores, vending machines, and e-commerce.
• Nature Made Dietary supplement and vitamin brand distributed in the US through mass retail, drugstores, and e-commerce channels.
• SOYJOY Plant-based nutritional snack bars sold globally through convenience and grocery channels.
• Calorie Mate
• Oronamin C
• Bonafia / BonCurry
• Otsuka Pharmaceutical Factory IV Solutions Large-volume sterile IV solutions and clinical nutrition products manufactured by Otsuka Pharmaceutical Factory and supplied to hospital pharmacies globally.
• Ulefnersen (antisense oligonucleotide) Licensed antisense oligonucleotide therapy developed by Ionis, added to Otsuka's rare-disease and neurology pipeline.
• Araris Biotech ADC Pipeline Next-generation antibody-drug conjugate platform acquired through Araris Biotech, intended to support three clinical-stage ADC candidates from Taiho Pharmaceutical.
• TS-1 and TAS-102 Oncology Products
• ABILIFY MAINTENA

Quantifiable outcome

• TSND-201 (Phase 2 IMPACT-1 trial): Met primary endpoint, demonstrating rapid improvements in PTSD symptoms. FDA Breakthrough Therapy Designation received July 2025.
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• FDA (National Priority Voucher for psychedelics)minorOthers · 29 April 2026Otsuka received a FDA National Priority Voucher as part of the psychedelic treatments development ecosystem. The FDA issues these vouchers to incentivize development of treatments for rare pediatric diseases and neglected tropical diseases.
• Fangzhou Inc.minorStrategic or Co-development Partner · 19 March 2026Fangzhou Inc., an AI-driven chronic disease management platform in China, partnered with Otsuka (among other pharma companies including Novo Nordisk and Innovent Biologics) as part of its strategic pharmaceutical partnerships ecosystem. Fangzhou's platform serves 56.4 million registered users and works with pharma companies for chronic care.
• LundbeckcoreStrategic or Co-development Partner · 12 March 2026Otsuka and Lundbeck have a long-standing global collaboration in psychiatry, with Lundbeck co-developing and co-commercializing REXULTI (brexpiprazole). The partnership competes with Axsome's newly approved Auvelity for Alzheimer's agitation. They also collaborated on brexpiprazole + sertraline for PTSD (received FDA advisory committee rejection). Health Canada approved ABILIFY ASIMTUFII (aripiprazole) as the first-and-only once-every-two-months LAI for schizophrenia and bipolar I disorder maintenance.
• Harbour BioMed (licensing)minorStrategic or Co-development Partner · 3 February 2026Otsuka entered a licensing collaboration with Harbour BioMed, contributing to Harbour BioMed's 314.6% year-over-year revenue increase in 2025. The deal structure includes milestone payments and licensing fees.
• Harbour BioMedminorStrategic or Co-development Partner · 20 June 2025Harbour BioMed entered a global strategic collaboration with Otsuka to advance BCMAxCD3 bispecific T-cell engagers. Harbour BioMed's profit alert cited the Otsuka collaboration as contributing to its dramatically improved 2025 financial results (profit up from $2.7M to ~$92M).
• ICU Medical (joint venture for IV solutions)coreStrategic or Co-development Partner · 23 May 2025ICU Medical and Otsuka Pharmaceutical Factory created a joint venture (JV) to bolster IV solutions manufacturing and innovation in North America. Otsuka invested $200 million in the JV, creating a global IV solutions powerhouse. The JV aims to strengthen North American manufacturing of IV solutions.
• Wellcome TrustminorStrategic or Co-development Partner · 15 May 2025Recor Medical (Otsuka Medical Devices subsidiary) collaborates with the Wellcome Trust on hypertension awareness initiatives and treatment access. World Hypertension Day 2026 marked Otsuka's global action on hypertension awareness.
• Ionis Pharmaceuticals (ulefnersen licensing)coreStrategic or Co-development Partner · 23 November 2024Otsuka gained global licensing rights from Ionis to ulefnersen, an antisense oligonucleotide therapy. This adds to Otsuka's rare disease/neurology pipeline beyond its existing psychiatric franchise.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Axsome Therapeutics: US CNS-focused biotech whose Auvelity directly competes with Otsuka's Rexulti in Alzheimer's agitation. Highly relevant emerging competitor in Otsuka's core CNS franchise.

Broad incumbents

• Pfizer: Global pharmaceutical conglomerate with extensive CNS, oncology, and consumer health portfolio. Broad incumbent comparable in scale, therapeutic-area breadth, and global MR-driven commercial model.
• Johnson & Johnson: Global healthcare conglomerate with pharmaceuticals, medical devices, and consumer health divisions. Comparable to Otsuka's pharma + device + consumer three-pillar model and recently invested alongside Otsuka in SonoThera.
• AbbVie: Global pharmaceutical leader with major CNS franchise (Vraylar) and consumer healthcare spinoff (Allergan Aesthetics). Comparable as a large-scale diversified pharma with overlapping psychiatric and specialty care portfolios.

Direct peers

• Lundbeck: Danish CNS-specialized pharmaceutical company and Otsuka's long-standing partner on REXULTI/brexpiprazole. Direct peer in psychiatric/neurological indications and the co-development structure is a strong basis for comparability.
• Daiichi Sankyo: Japanese pharmaceutical leader with strong oncology franchise (Enhertu) and consumer healthcare presence. Comparable as a Japan-listed diversified pharma with specialty pipeline depth and consumer health brands.
• Eisai: Japanese pharmaceutical company with strong CNS and neurology focus (Leqembi for Alzheimer's, Dayvigo). Highly comparable to Otsuka's psychiatric/neurology franchise and Asia-led commercial model.
• Takeda Pharmaceutical: Japan's largest pharmaceutical company with diversified pharma, rare disease, and consumer healthcare operations. Most directly comparable Japanese pharma conglomerate by scale, geographic footprint, and CNS/specialty pharma focus.
• Sumitomo Pharma: Japanese pharmaceutical group with CNS, oncology, and regenerative medicine focus. Comparable mid-cap Japanese pharma with similar CNS pipeline bets and US commercialization infrastructure.
• Astellas Pharma: Major Japanese pharmaceutical company focused on specialty therapeutics including oncology, urology, and neurology. Comparable as a Japan-headquartered specialty pharma with similar global commercial structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/otsuka-holdings

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Holdings